
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : FZ002-037
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Jiangsu Simcere Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Fermion, Simcere Exclusive License for China’s First SSTR4 Agonist
Details : Under the agreement, Simcere will gain exclusive rights to develop and commercialize FZ002-037 in Greater China. It is being evaluated for the treatment of Chronic Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 17, 2025
Lead Product(s) : FZ002-037
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Jiangsu Simcere Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : FZ008-145
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Study of FZ008-145 in Healthy Subjects.
Details : FZ008-145 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 13, 2024
Lead Product(s) : FZ008-145
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : FZ007-119
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Fermion's TYK2 JH2 Inhibitor FZ007-119 Granted IND Approval by China NMPA
Details : FZ007-119 is a third-generation JAK inhibitor targeting TYK2 JH2. It's IND application is approved after preclinical studies for plaque psoriasis, inflammatory bowel disease & rheumatoid arthritis
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 05, 2024
Lead Product(s) : FZ007-119
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
